# A Multicentre Study on Rifaximin in Post-operative Endoscopic Crohn's Disease Recurrence Prevention

> **NCT03537157** · PHASE2 · TERMINATED · sponsor: **Alfasigma S.p.A.** · enrollment: 43 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** Rifaximin delayed release tablets
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03537157
- **Lead sponsor:** Alfasigma S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-16
- **Primary completion:** 2020-07-15
- **Final completion:** 2020-07-29
- **Target enrollment:** 43 (ACTUAL)
- **Why stopped:** The decision to prematurely close the trial recruitment period was taken due to the difficulties in the recruitment of patients. This decision has not been triggered by any unexpected safety signals identified during the study conduction.
- **Last updated:** 2021-09-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03537157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03537157, "A Multicentre Study on Rifaximin in Post-operative Endoscopic Crohn's Disease Recurrence Prevention". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03537157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*